Lixte Biotechnology Holdings LIXT 深 沪
等待开盘 12-18 09:30:00 美东时间
3.96
-0.140
-3.41%
华盛通- 最 高4.14
- 今 开4.03
- 成交量 14.37万股
- 最 低 3.75
- 昨 收 4.10
- 总市值 1806.31万
- 52周最高 6.26
- 市盈率 静 --
- 换手率 3.15%
- 52周最低 0.64
- 委 比 49.90%
- 总股本 456.14万
- 历史最高 71.90
- 量 比 1.72
- 振 幅 9.51%
- 历史最低 0.64
- 每 手 1
- 风险率 1.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lixte Biotechnology Holds Annual Meeting, Approves Key Issues
The latest update is out from Lixte Biotechnology Holdings ( ($LIXT) ). On Dece...
12-12 04:17
LIXTE Biotechnology Acquires Liora Technologies Europe
LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT) a biotech company focused on advancing cancer treatments, today announced it has completed the acquisition of Liora Technologies Europe Ltd., a
11-25 21:33
LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3
LIXTE Biotechnology Holdings, Inc. announced that its CEO, Geordan Pursglove, will present at the Spartan Capital Investor Conference 2025 in New York on November 3, 2025. The company will also hold one-on-one meetings with investors. LIXTE is developing LB-100, a first-in-class PP2A inhibitor for cancer treatment, which is currently in clinical trials for ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma.
10-29 12:00
LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
LIXTE Biotechnology Holdings, Inc. announced its Q4 2025 priorities, including advancing its lead compound LB-100, pursuing acquisitions of complementary oncology assets, and enhancing operational readiness. The company is in advanced negotiations for potential transactions aligned with its strategic goals.
10-16 12:00
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Genprex (NASDAQ:GNPX) stock increased by 88.1% to $0.47 during Wednesd...
10-15 20:09
Lixte Biotechnology Invests $2.6M in Cryptocurrencies
The latest announcement is out from Lixte Biotechnology Holdings ( ($LIXT) ). O...
09-12 01:47
LIXTE Biotechnology makes $2.6M initial purchase of digital currency
LIXTE Biotechnology (NASDAQ:LIXT) said on Wednesday that it has made an initial purchase of cryptocurrencies to further diversify its treasury holdings and for potential acquisitions. The company purc...
09-11 04:17
LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions
LIXTE Biotechnology Holdings, Inc. ("LIXTE") announced the purchase of 10.5 Bitcoin (BTC) and 300 Ethereum (ETH) totaling approximately $2.6 million to diversify its treasury and facilitate potential acquisitions. Cryptocurrency now constitutes about 43.6% of LIXTE's treasury holdings, with the Board approving up to 50% allocation to digital assets. CEO Geordan Pursglove emphasized the strategic importance of integrating cryptocurrencies to enhan...
09-10 20:05
Lixte Biotechnology appoints new CFO and board members
Lixte Biotechnology (NASDAQ:LIXT) appointed Peter Stazzone as chief financial officer. Lourdes Felix and Guy Primus joined LIXTE’s board of directors. Former CFO Robert Weingarten and board members Ba...
09-03 20:18
LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer
LIXTE Biotechnology Holdings announced the addition of Peter Stazzone as Chief Financial Officer and Lourdes Felix and Guy Primus to its Board of Directors, succeeding Bas van der Baan and René Bernards. The company has relocated its headquarters to Boca Raton, Florida, aiming to enhance operational efficiency and reduce costs. Stazzone brings over 20 years of financial management experience, while Felix and Primus add expertise in corporate fina...
09-03 12:00
